Immunoclin (Immunoclin) Equity-to-Asset : 0.86 (As of Oct. 2014)

Immunoclin Equity-to-Asset Chart

Immunoclin Quarterly Data
	May11	Aug11	Nov11	Feb12	May12	Aug12	Nov12	Feb13	May13	Aug13	Nov13	Apr14	Jul14	Oct14
Equity-to-Asset	Get a 7-Day Free Trial									0.86	0.84	0.94	0.91	0.86

Competitive Comparison of Immunoclin's Equity-to-Asset

For the Biotechnology subindustry, Immunoclin's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunoclin's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunoclin's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Immunoclin's Equity-to-Asset falls into.

Immunoclin Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Immunoclin's Equity to Asset Ratio for the fiscal year that ended in Jan. 2014 is calculated as

Immunoclin's Equity to Asset Ratio for the quarter that ended in Oct. 2014 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunoclin  (GREY:IMCL) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Immunoclin Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Immunoclin's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunoclin (Immunoclin) Business Description